Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Innate Pharma Presents Preclinical Efficacy Of Its Pre-IND Drug Candidate IPH45, A Novel Nectin-4 Antibody Drug Conjugate At AACR 2024

Author: Benzinga Newsdesk | April 10, 2024 02:55am
  • IPH45 is a novel and differentiated exatecan-Antibody Drug Conjugate targeting Nectin-4
  • In PDX models of urothelial tumors, IPH45 has stronger activity than approved Nectin-4 targeting EV. IPH45 shows anti-tumor efficacy in various solid tumor and EV-refractory models
  • Preclinical efficacy and toxicology data support further development of IPH45 which is progressing towards the clinic with IND planned in 2024

Posted In: IPHA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist